Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

SeriouslyWhy Feb. 12 at 1:25 AM

$PFE vktx misses earnings by 53% and up 10% wtf

1 · Reply

Laurapicksright Feb. 12 at 12:41 AM

$NVCR Massive massive news 😍 watching $PFE $AMZN $TSLA $AMD

0 · Reply

Blizzy Feb. 11 at 10:51 PM

$PFE breaking $28, not yet!! And until it does it’s a nothing sandwich 😤⏳

0 · Reply

aguaman Feb. 11 at 10:00 PM

$IBM $PFE January 24. Pfizer goes X. It is moving up strong, and it’s still pays 6%. IBM at 2 1/2% ain’t bad. Good luck all longs!

0 · Reply

TalkMarkets Feb. 11 at 9:50 PM

#Pfizer Reports Strong #Earnings Outlook - Unusual Call Options Activity Shows Investors Are Bullish $PFE https://talkmarkets.com/content/options/pfizer-reports-strong-earnings-outlook-unusual-call-options-activity-shows-investors-are-bullish?post=556780

0 · Reply

JMO487 Feb. 11 at 8:54 PM

$PFE looks like the big dogs are accumulating calls and shares for potential short squeeze above 30$ next week

0 · Reply

JLInvest Feb. 11 at 8:32 PM

$SPY $SPX positioning is defensive. Look at the moves in names like $PFE $T and $VZ Sell growth stocks to own names with strong dividends that pay you a solid return if equity market performance ends.

0 · Reply

doubleuptwice Feb. 11 at 6:57 PM

$PFE will have a read on this tomorrow unfortunately if I’m looking at it today looks like a close this week under $27.50

1 · Reply

jackofalltrade Feb. 11 at 6:18 PM

$PFE As of 1/30 short interest was way up in this stock. Any thoughts on why that is? 1/30/26 was 143 million. 1/31/25 was only 73.5 million.

0 · Reply

Willieberich Feb. 11 at 6:16 PM

$PFE This is doing great .no big moves. Nice and steady..

0 · Reply

Pfizer: A Great Opportunity Post Earnings

Feb 11, 2026, 4:06 PM EST - 6 hours ago

2 Urgent Sells And 2 No Brainer Dividend Buys

ABBV AEP AMGN BMY ESS HASI HD

Feb 11, 2026, 8:56 AM EST - 14 hours ago

Is Pfizer Stock Now A Value Trap?

Feb 10, 2026, 3:20 PM EST - 1 day ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 8, 2026, 10:19 PM EST - 3 days ago

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Feb 6, 2026, 2:55 PM EST - 5 days ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 7:25 AM EST - 5 days ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

ARCC ARLP CNQ EPD EQNR F FINV

Feb 6, 2026, 6:45 AM EST - 5 days ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 5, 2026, 7:09 PM EST - 6 days ago

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Feb 3, 2026, 3:00 PM EST - 8 days ago

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 2:02 PM EST - 8 days ago

Pfizer: Messy Q4 Earnings Mask An Improving Business

Feb 3, 2026, 1:27 PM EST - 8 days ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Feb 3, 2026, 12:00 PM EST - 8 days ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 11:56 AM EST - 8 days ago

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Feb 3, 2026, 11:17 AM EST - 8 days ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Feb 3, 2026, 10:15 AM EST - 8 days ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 8:50 AM EST - 8 days ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:17 AM EST - 8 days ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Feb 3, 2026, 7:28 AM EST - 8 days ago

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Feb 3, 2026, 7:21 AM EST - 8 days ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:18 AM EST - 8 days ago

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Feb 3, 2026, 7:02 AM EST - 8 days ago

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.

Feb 3, 2026, 6:57 AM EST - 8 days ago

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Feb 3, 2026, 6:50 AM EST - 8 days ago

Pfizer beats fourth-quarter profit estimates on strong drug demand

Feb 3, 2026, 6:45 AM EST - 8 days ago

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Feb 3, 2026, 6:45 AM EST - 8 days ago

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Feb 3, 2026, 6:40 AM EST - 8 days ago

Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

Feb 2, 2026, 8:42 AM EST - 9 days ago

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

SNY

Feb 2, 2026, 1:01 AM EST - 9 days ago

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Jan 31, 2026, 3:47 AM EST - 11 days ago

5 'Safer' Dividend Buys In Barron's 23 Better January Bets Than T-Bill

BBY CAG EQR FRT KEY LYB MAA

Jan 30, 2026, 10:31 AM EST - 12 days ago

Pfizer: Buyer Beware, The Risk Outweighs The Reward

Jan 30, 2026, 7:30 AM EST - 12 days ago

Why Dividend Stocks Are Essential For What Comes Next

AM CAG EPD ET KMI LLY MPLX

Jan 29, 2026, 9:00 AM EST - 13 days ago

Pfizer: A High-Yield Pharma At A Turning Point

Jan 27, 2026, 4:52 PM EST - 15 days ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

ABBV LLY

Jan 27, 2026, 7:40 AM EST - 15 days ago

Pfizer vs. Merck Stock And JNJ

Jan 27, 2026, 6:02 AM EST - 15 days ago

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Jan 23, 2026, 10:33 AM EST - 19 days ago

Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)

Jan 23, 2026, 9:54 AM EST - 19 days ago

December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs

AGNC AGNCP ARLP ECC EFC ET FBRT

Jan 20, 2026, 12:34 PM EST - 22 days ago

Pfizer CEO Albert Bourla: U.S. drug prices are coming down

Jan 20, 2026, 12:18 PM EST - 22 days ago

Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry

NVO

Jan 20, 2026, 7:11 AM EST - 22 days ago

Novavax enters license agreement with Pfizer for vaccine development

NVAX

Jan 20, 2026, 2:19 AM EST - 22 days ago

Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits

Jan 19, 2026, 8:10 PM EST - 23 days ago

Invesco Equity And Income Fund Q4 2025 Portfolio Positioning And Performance

BDX DD MSFT ORCL PH Q SLB

Jan 19, 2026, 2:20 PM EST - 23 days ago

MoneyShow's Best Investment Ideas For 2026: Part 7

PLD PLG PM QUIK RCAT

Jan 16, 2026, 1:08 PM EST - 26 days ago

Pfizer: Rebound Has Just Started

Jan 15, 2026, 8:58 AM EST - 27 days ago

Pfizer: The Most Intriguing Value Play Of 2026

Jan 13, 2026, 6:11 AM EST - 4 weeks ago

Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Jan 12, 2026, 6:43 PM EST - 4 weeks ago

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra

Jan 12, 2026, 3:16 PM EST - 4 weeks ago

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 10, 2026, 10:00 AM EST - 4 weeks ago

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

SeriouslyWhy Feb. 12 at 1:25 AM

$PFE vktx misses earnings by 53% and up 10% wtf

1 · Reply

Laurapicksright Feb. 12 at 12:41 AM

$NVCR Massive massive news 😍 watching $PFE $AMZN $TSLA $AMD

0 · Reply

Blizzy Feb. 11 at 10:51 PM

$PFE breaking $28, not yet!! And until it does it’s a nothing sandwich 😤⏳

0 · Reply

aguaman Feb. 11 at 10:00 PM

$IBM $PFE January 24. Pfizer goes X. It is moving up strong, and it’s still pays 6%. IBM at 2 1/2% ain’t bad. Good luck all longs!

0 · Reply

TalkMarkets Feb. 11 at 9:50 PM

0 · Reply

JMO487 Feb. 11 at 8:54 PM

$PFE looks like the big dogs are accumulating calls and shares for potential short squeeze above 30$ next week

0 · Reply

JLInvest Feb. 11 at 8:32 PM

0 · Reply

doubleuptwice Feb. 11 at 6:57 PM

$PFE will have a read on this tomorrow unfortunately if I’m looking at it today looks like a close this week under $27.50

1 · Reply

jackofalltrade Feb. 11 at 6:18 PM

$PFE As of 1/30 short interest was way up in this stock. Any thoughts on why that is? 1/30/26 was 143 million. 1/31/25 was only 73.5 million.

0 · Reply

Willieberich Feb. 11 at 6:16 PM

$PFE This is doing great .no big moves. Nice and steady..

0 · Reply

ProTraderColin Feb. 11 at 5:44 PM

$PFE coming into a big test when you zoom out. Give us 30+!!!

0 · Reply

PFElinepfrenzy1990 Feb. 11 at 5:41 PM

$PFE - Bonkers

0 · Reply

thegreatkaspi Feb. 11 at 5:30 PM

$PFE this thing is a fucken beast since earnings. multiple green days while other names getting shred to pieces during earnings.

1 · Reply

_Crim_Jamer_ Feb. 11 at 5:22 PM

$PFE which banks are buying the rotation to pharma?

0 · Reply

PFElinepfrenzy1990 Feb. 11 at 4:45 PM

$PFE - UnPfizery behaviour. My shitco got possessed.

0 · Reply

Maniacal_Laugh Feb. 11 at 4:15 PM

$PFE $XBI $SRPT $SGMO its coming. Next move is big and its up

0 · Reply

free2dream Feb. 11 at 4:13 PM

$PFE WE MIGHT HAVE A MULTI YEAR BREAK OUT ! $XBI $SRPT $SGMO

0 · Reply

Tiger65 Feb. 11 at 3:59 PM

$WU $PFE $VTRS Little reminder: If you are bullish on a stock and want to help it go up better buy ITM options. The broker has to buy the underlying to hedge its position.

0 · Reply

ZacksResearch Feb. 11 at 3:56 PM

$PFE staring down a patent cliff — can new & acquired drugs really fill the gap? ⚠️ With COVID sales fading and a 2026-2030 patent cliff threatening key blockbusters, Pfizer is betting big on its pipeline and recent acquisitions to reignite growth. The setup is clear: replace lost revenue or risk a serious slowdown. Can the new portfolio carry the weight? Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2853815/can-pfizers-new-acquired-drugs-offset-its-looming-patent-cliff?cid=sm-stocktwits-2-2853815-teaser-33037&ADID=SYND_STOCKTWITS_TWEET_2_2853815_TEASER_33037

1 · Reply

LLMAgent Feb. 11 at 3:06 PM

$GOOGL $GOOG But I agree, very frustrating price action, specially if you’re used to all the green the last year AND know that the market is wrong and overreacting. Fortunately, years of being a $PFE bagholder have immunised me to a stock being continuously in the red (in case of PFE, deservedly so.)

1 · Reply

ZacksResearch Feb. 11 at 2:56 PM

$PFE facing a challenging road ahead! ⚠️ Despite new launches boosting non-COVID revenues by 6% operationally in 2025, Pfizer's facing major patent cliffs and a Zacks Rank #4 (Sell). With shares trading at a P/E of 9.33, well below the industry average, is this a value trap? Opportunity assessment here 👉 https://www.zacks.com/stock/news/2853815/can-pfizers-new-acquired-drugs-offset-its-looming-patent-cliff?cid=sm-stocktwits-2-2853815-body-33036&ADID=SYND_STOCKTWITS_TWEET_2_2853815_BODY_33036

0 · Reply

ajbski Feb. 11 at 2:40 PM

$NVAX 🚀Novavax’s trial design is more in line with current FDA expectations than Moderna's was. By testing against the high-dose standard for seniors, Novavax has cleared a regulatory hurdle that Moderna tripped over.🚀 $SNY $MRNA $PFE #Biotech

0 · Reply

Market Cap	156.98B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	8.37
Forward PE	9.09
Profit Margin	12.42%
Debt to Equity Ratio	0.66

Volume	41,699,300
Avg Vol	50,277,535
Day's Range	N/A - N/A
Shares Out	5.69B
Stochastic %K	92%
Beta	0.47
Analysts	Sell
Price Target	$28.35